Fig. 2: K–M DMFS curves according to the RS among LARC patient subgroups.
From: Predicting distant metastasis and chemotherapy benefit in locally advanced rectal cancer
a The primary cohort (upper: stage II, n = 87; lower: stage III, n = 89). b Validation cohort 1 (upper: stage II, n = 23; lower: stage III, n = 131). c Validation cohort 2 (upper: stage II, n = 42; lower: stage III, n = 108). d Validation cohort 3 (upper: stage II, n = 53; lower: stage III, n = 96). p values were calculated using two-sided log-rank test. RS radiomic signature; HR hazard ratio; DMFS distant metastasis-free survival; LARC locally advanced rectal cancer. Source data are provided as a Source Data file.
